Frequency of Tuberculosis in Psoriasis Patients

Bezmialem Vakif University719 enrolled

Overview

Aim of this study is evaluation of patients receiving TNF inhibitor therapy in terms of tuberculosis at the end of 15 years in a single center.

Aim of this study is evaluation of patients receiving TNF inhibitor therapy in terms of tuberculosis at the end of 15 years in a single center. TNF inhibitor therapy may increase the risk for tuberculosis infection. According to medical data in our hospital in last 15 years, tuberculosis rate of psoriasis patients receiving etanercept, adalimumab and infliximab will be compared.

Study Type

OBSERVATIONAL

Enrollment

719

Conditions

Psoriasis Vulgaris Tuberculosis

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * psoriasis patients receiving TNF inhibitor therapy Exclusion Criteria: * patients without TNF inhibitor therapy

Locations (1)

Bezmialem Vakif University Hospital

Istanbul, Turkey (Türkiye)

Outcomes

Primary Outcomes

tuberculosis rate

number of patients with tuberculosis infection after receiving TNF inhibitor therapy

Time frame: patients from June 2007 to January 2023, up to 15 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.